Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Kiora Pharmaceuticals Inc. (KPRX)

Kiora Pharmaceuticals Inc. (KPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,944
  • Shares Outstanding, K 3,678
  • Annual Sales, $ 16,020 K
  • Annual Income, $ 3,590 K
  • EBIT $ -8 M
  • EBITDA $ -8 M
  • 60-Month Beta -0.75
  • Price/Sales 0.50
  • Price/Cash Flow 1.74
  • Price/Book 0.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -1.04
  • Growth Rate Est. (year over year) +96,157.69%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.76 +22.41%
on 11/25/25
2.23 -3.14%
on 12/11/25
+0.29 (+15.51%)
since 11/21/25
3-Month
1.76 +22.41%
on 11/25/25
2.95 -26.78%
on 10/08/25
-0.45 (-17.24%)
since 09/22/25
52-Week
1.76 +22.41%
on 11/25/25
4.18 -48.33%
on 06/03/25
-1.11 (-33.94%)
since 12/20/24

Most Recent Stories

More News
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

Encinitas, California--(Newsfile Corp. - December 1, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office issued a new patent (US-12,472,263) on...

KPRX : 2.16 (unch)
Kiora Pharmaceuticals Reports Third Quarter 2025 Results; Company Advances Pipeline with Two Actively Enrolling Phase 2 Clinical Trials for Retinal Diseases

Encinitas, California--(Newsfile Corp. - November 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced third quarter 2025 financial results and provided an update...

KPRX : 2.16 (unch)
Kiora Pharmaceuticals Joins RARE-X Vision Consortium Promoting Collaboration and Development of New Treatments for Rare Ocular Disorders

ENCINITAS, Calif. and WASHINGTON D.C. , Oct. 30, 2025 /PRNewswire/ -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) and Global Genes today announced that Kiora has joined Global Genes' RARE-X Vision...

KPRX : 2.16 (unch)
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025

Encinitas, California--(Newsfile Corp. - October 15, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an ophthalmology panel at the upcoming 2025 Maxim Growth...

KPRX : 2.16 (unch)
Kiora Pharmaceuticals to Webcast On-Demand Presentation at The H.C. Wainwright 27th Annual Global Investment Conference

Encinitas, California--(Newsfile Corp. - September 4, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its Chief Financial Officer, Melissa Tosca, CPA, will showcase the Company's...

KPRX : 2.16 (unch)
Kiora Pharmaceuticals Reports Second Quarter 2025 Results; Company Advances Pipeline with Two Active Phase 2 Clinical Trials for Retinal Diseases

Encinitas, California--(Newsfile Corp. - August 8, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced second quarter 2025 financial results and provided an update...

KPRX : 2.16 (unch)
Kiora Pharmaceuticals to Showcase Its Retinal Disease Therapeutic Pipeline at The H.C. Wainwright 5th Annual Ophthalmology Virtual Conference

Encinitas, California--(Newsfile Corp. - August 7, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that its President and CEO, Brian M. Strem, Ph.D., will showcase the Company's pipeline...

KPRX : 2.16 (unch)
Vicarious Surgical Announces Leadership Transition: Stephen From, Healthcare Industry Veteran, Appointed Chief Executive Officer

Adam Sachs, Co-Founder, to Remain on as President

RBOT : 2.18 (+0.46%)
KPRX : 2.16 (unch)
Kiora Pharmaceuticals Granted U.S. Patent Expanding Protection for KIO-104 in the Treatment of Ocular Disease

Encinitas, California--(Newsfile Corp. - July 22, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced it has received a patent (US Patent No. 12,364,680) covering KIO-104 for the treatment...

KPRX : 2.16 (unch)
Kiora Pharmaceuticals and Senju Pharmaceutical Partner on KIO-301 for the Treatment of Retinal Diseases in Asia

Total potential deal value of $110 million plus royaltiesKiora to receive an immediate $1.25 million exclusive option feeIf the option is exercised, Kiora will receive an additional mid-single digit million...

KPRX : 2.16 (unch)

Business Summary

Kiora Pharmaceuticals Inc. is a clinical-stage specialty pharmaceutical company. It involved in developing and commercializing products for treating ophthalmic diseases. The company's product pipeline includes KIO-301, KIO-101 and KIO-201. Kiora Pharmaceuticals Inc., formerly known as EyeGate Pharmaceuticals...

See More

Key Turning Points

3rd Resistance Point 2.32
2nd Resistance Point 2.27
1st Resistance Point 2.21
Last Price 2.16
1st Support Level 2.10
2nd Support Level 2.05
3rd Support Level 1.99

See More

52-Week High 4.18
Fibonacci 61.8% 3.26
Fibonacci 50% 2.97
Fibonacci 38.2% 2.69
Last Price 2.16
52-Week Low 1.76

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar